Emerging immune targets for the treatment of multiple myeloma

We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuxima...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2018-02, Vol.10 (4), p.265-282
Main Authors: Sohail, Atif, Mushtaq, Adeela, Iftikhar, Ahmad, Warraich, Zabih, Kurtin, Sandra E, Tenneti, Pavan, McBride, Ali, Anwer, Faiz
Format: Article
Language:English
Subjects:
adoptive cell therapy
antibodies
antibody therapeutics
Antigens
Bevacizumab
Bone marrow
Cancer therapies
CD19 antigen
CD38 antigen
Cell growth
Chimeric antigen receptors
chimeric antigen T cells
Clinical trials
Cytotoxicity
Drug dosages
Growth factors
Immunoglobulins
Immunosuppressive agents
Immunotherapy
Leukemia
Lymphocytes
Lymphocytes B
Lymphocytes T
Monoclonal antibodies
Multiple myeloma
Pathogenesis
Pembrolizumab
Stem cells
Studies
Systematic Review
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2017-0136